Tumor escape mechanisms: potential role of soluble HLA antigens and NK cells activating ligands.
暂无分享,去创建一个
[1] X. Chen,et al. NKG2D Ligands Expression and NKG2D‐Mediated Cytotoxicity in Human Laryngeal Squamous Carcinoma Cells , 2008, Scandinavian journal of immunology.
[2] J. Fernández-Morera,et al. Soluble MHC class I chain-related protein B serum levels correlate with disease activity in relapsing-remitting multiple sclerosis. , 2008, Human immunology.
[3] Philippe Moreau,et al. HLA-G: from biology to clinical benefits. , 2008, Trends in immunology.
[4] T. Kirita,et al. Association between soluble MICA levels and disease stage IV oral squamous cell carcinoma in Japanese patients. , 2008, Human immunology.
[5] D. Neuberg,et al. MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma , 2008, Proceedings of the National Academy of Sciences.
[6] A. Aguilar-Lemarroy,et al. Augmented serum level of major histocompatibility complex class I-related chain A (MICA) protein and reduced NKG2D expression on NK and T cells in patients with cervical cancer and precursor lesions , 2008, BMC Cancer.
[7] H. Wiendl,et al. Immune-refractory cancers and their little helpers--an extended role for immunetolerogenic MHC molecules HLA-G and HLA-E? , 2007, Seminars in cancer biology.
[8] S. Ferrone,et al. Soluble HLA-G: Are they clinically relevant? , 2007, Seminars in cancer biology.
[9] M. Gamerre,et al. Soluble MHC Class I chain-related molecule serum levels are predictive markers of implantation failure and successful term pregnancies following IVF. , 2007, Human reproduction.
[10] U. Beuers,et al. Soluble NKG2D ligands in hepatic autoimmune diseases and in benign diseases involved in marker metabolism. , 2007, Anticancer research.
[11] S. Ferrone,et al. Human neuroblastoma cells trigger an immunosuppressive program in monocytes by stimulating soluble HLA-G release. , 2007, Cancer research.
[12] Chi Ma,et al. RAET1E2, a Soluble Isoform of the UL16-binding Protein RAET1E Produced by Tumor Cells, Inhibits NKG2D-mediated NK Cytotoxicity* , 2007, Journal of Biological Chemistry.
[13] K. Tanabe,et al. Cancer immunoediting from immune surveillance to immune escape , 2007, Immunology.
[14] T. Moritz,et al. Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients. , 2007, Clinical immunology.
[15] N. Zavazava,et al. Soluble HLA revisited. , 2007, Leukemia research.
[16] J. Armitage,et al. Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease. , 2007, Leukemia research.
[17] E. Estey,et al. Levels of soluble HLA-I and β2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy , 2007, Leukemia.
[18] S. Ferrone,et al. A fresh look at an old story: revisiting HLA class II antigen expression by melanoma cells , 2006 .
[19] M. Büchler,et al. Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing γδ T cell cytotoxicity , 2006 .
[20] Judith E. Cartwright,et al. Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells. , 2006, Blood.
[21] A. Poggi,et al. Mechanisms of tumor escape: role of tumor microenvironment in inducing apoptosis of cytolytic effector cells , 2006, Archivum Immunologiae et Therapiae Experimentalis.
[22] S. Ferrone,et al. NK cell activating ligands on human malignant cells: molecular and functional defects and potential clinical relevance. , 2006, Seminars in cancer biology.
[23] R. Orenstein. Infections related to TNF-α inhibitors , 2006 .
[24] A. Moreau,et al. Expression and Release of HLA-E by Melanoma Cells and Melanocytes: Potential Impact on the Response of Cytotoxic Effector Cells1 , 2006, The Journal of Immunology.
[25] B. Minev,et al. Analyzing T cell responses: how to analyze cellular immune responses against tumor associated antigens , 2006, Apoptosis.
[26] S. Ferrone,et al. Immune selective pressure and HLA class I antigen defects in malignant lesions , 2006, Cancer Immunology, Immunotherapy.
[27] F. Hodi,et al. Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[28] H. Salih,et al. Soluble MICB in malignant diseases: analysis of diagnostic significance and correlation with soluble MICA , 2006, Cancer Immunology, Immunotherapy.
[29] H. Salih,et al. Release of MICB molecules by tumor cells: mechanism and soluble MICB in sera of cancer patients. , 2006, Human immunology.
[30] A. Steinle,et al. Proteolytic release of soluble UL16-binding protein 2 from tumor cells. , 2006, Cancer research.
[31] B. Branger,et al. Soluble HLA-G molecules increase during acute leukemia, especially in subtypes affecting monocytic and lymphoid lineages. , 2006, Neoplasia.
[32] H. Salih,et al. Soluble MICA in malignant diseases , 2006, International journal of cancer.
[33] S. Ferrone,et al. Antigen Presentation Machinery (APM) Modulation and Soluble HLA Molecules in the Tumor Microenvironment: Do They Provide Tumor Cells with Escape Mechanisms from Recognition by Cytotoxic T Lymphocytes? , 2006, Immunological investigations.
[34] N. Hayashi,et al. Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas. , 2005, Journal of hepatology.
[35] A. Poggi,et al. Cyclosporin A regulates human NK cell apoptosis induced by soluble HLA-I or by target cells. , 2005, Autoimmunity reviews.
[36] R. Bataille,et al. Total Soluble HLA Class I and Soluble HLA-G in Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance , 2005, Clinical Cancer Research.
[37] J. Letterio. TGF-β signaling in T cells: roles in lymphoid and epithelial neoplasia , 2005, Oncogene.
[38] L. Moretta,et al. Human natural killer cells: Molecular mechanisms controlling NK cell activation and tumor cell lysis. , 2005, Immunology letters.
[39] S. Ferrone,et al. Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications , 2005, Oncogene.
[40] J. Rodgers,et al. MHC class Ib molecules bridge innate and acquired immunity , 2005, Nature Reviews Immunology.
[41] S. Mark,et al. Soluble MHC-Peptide Complexes Induce Rapid Death of CD8+ CTL1 , 2005, The Journal of Immunology.
[42] A. Poggi,et al. Pertussis Toxin (PTX) B Subunit and the Nontoxic PTX Mutant PT9K/129G Inhibit Tat-Induced TGF-β Production by NK Cells and TGF-β-Mediated NK Cell Apoptosis 1 , 2005, The Journal of Immunology.
[43] K. Knutson,et al. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy , 2005, Cancer Immunology, Immunotherapy.
[44] S. Ferrone,et al. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. , 2004, Neoplasia.
[45] Federico Garrido,et al. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape , 2004, Cancer Immunology, Immunotherapy.
[46] L. Durrant,et al. Cancer vaccines entering Phase III clinical trials , 2003, Expert opinion on emerging drugs.
[47] S. Negrini,et al. IFN‐γ production in human NK cells through the engagement of CD8 by soluble or surface HLA class I molecules , 2003, European journal of immunology.
[48] D. Stolke,et al. Secretion of sHLA-G molecules in malignancies. , 2003, Seminars in cancer biology.
[49] M. Bernard,et al. HLA-G and lymphoproliferative disorders. , 2003, Seminars in cancer biology.
[50] F. Bouet,et al. Constitutive expression of TGF-bêta1, interleukin-6 and interleukin-8 by tumor cells as a major component of immune escape in human ovarian carcinoma. , 2003, European cytokine network.
[51] H. Rammensee,et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. , 2003, Blood.
[52] N. Hayashi,et al. Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid , 2003, International journal of cancer.
[53] D. Ruiter,et al. On the biological relevance of MHC class II and B7 expression by tumour cells in melanoma metastases , 2003, British Journal of Cancer.
[54] B. Seliger,et al. HLA-G and MIC expression in tumors and their role in anti-tumor immunity. , 2003, Trends in immunology.
[55] S. Ferrone,et al. Soluble HLA‐A,‐B,‐C and ‐G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation , 2003, European journal of immunology.
[56] P. Shrikant,et al. In Vivo Augmentation of Tumor-Specific CTL Responses by Class I/Peptide Antigen Complexes on Microspheres (Large Multivalent Immunogen)1 , 2003, The Journal of Immunology.
[57] A. Poggi,et al. Soluble HLA class I induces NK cell apoptosis upon the engagement of killer-activating HLA class I receptors through FasL-Fas interaction. , 2002, Blood.
[58] S. Ferrone,et al. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. , 2002, Cancer research.
[59] R. Schreiber,et al. Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.
[60] C. Yee,et al. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation , 2002, Nature.
[61] H. Rammensee,et al. Cutting Edge: Down-Regulation of MICA on Human Tumors by Proteolytic Shedding , 2002, The Journal of Immunology.
[62] G. Bernardi,et al. Transendothelial Migratory Pathways of Vδ1+TCRγδ+ and Vδ2+TCRγδ+ T Lymphocytes from Healthy Donors and Multiple Sclerosis Patients: Involvement of Phosphatidylinositol 3 Kinase and Calcium Calmodulin-Dependent Kinase II1 , 2002, The Journal of Immunology.
[63] Francesco M Marincola,et al. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? , 2002, Journal of the National Cancer Institute.
[64] É. Vivier,et al. Lymphocyte activation via NKG2D: towards a new paradigm in immune recognition? , 2002, Current opinion in immunology.
[65] M. Weller,et al. A Functional Role of HLA-G Expression in Human Gliomas: An Alternative Strategy of Immune Escape1 , 2002, The Journal of Immunology.
[66] A. Poggi,et al. Soluble HLA class I molecules induce natural killer cell apoptosis through the engagement of CD8: evidence for a negative regulation exerted by members of the inhibitory receptor superfamily. , 2002, Blood.
[67] F. Puppo,et al. Soluble HLA Class I Molecules/CD8 Ligation Trigger Apoptosis of CD8 Cells by Fas/Fas-Ligand Interaction , 2002, TheScientificWorldJournal.
[68] R. Schwartz. Faculty Opinions recommendation of Antigen-specific modulation of an immune response by in vivo administration of soluble MHC class I tetramers. , 2001 .
[69] J. Bluestone,et al. Antigen-Specific Blockade of T Cells In Vivo Using Dimeric MHC Peptide1 , 2001, The Journal of Immunology.
[70] Eric O Long,et al. Cutting Edge: Induction of IFN-γ Production but Not Cytotoxicity by the Killer Cell Ig-Like Receptor KIR2DL4 (CD158d) in Resting NK Cells , 2001, The Journal of Immunology.
[71] S. Ugurel,et al. Soluble human leukocyte antigen–G serum level is elevated in melanoma patients and is further increased by interferon‐α immunotherapy , 2001 .
[72] H. Kuwano,et al. Clinical significance of soluble form of HLA class I molecule in Japanese patients with pancreatic cancer. , 2001, Human immunology.
[73] V. Appay,et al. A novel approach to antigen-specific deletion of CTL with minimal cellular activation using alpha3 domain mutants of MHC class I/peptide complex. , 2001, Immunity.
[74] R. Armitage,et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. , 2001, Immunity.
[75] T. Waldmann,et al. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. , 2001, Immunity.
[76] S. Demaria,et al. Soluble HLA proteins with bound peptides are released from the cell surface by the membrane metalloproteinase. , 2000, Human immunology.
[77] A. Merlo,et al. Soluble HLA class I/CD8 ligation triggers apoptosis in EBV-specific CD8+ cytotoxic T lymphocytes by Fas/Fas-ligand interaction. , 2000, Human immunology.
[78] D. Huhn,et al. Targeting of Natural Killer-Like T Immunologic Effector Cells Against Leukemia and Lymphoma Cells by Reverse Antibody-Dependent Cellular Cytotoxicity , 2000, Journal of immunotherapy.
[79] S. Ferrone,et al. Soluble human MHC class I molecules induce soluble Fas ligand secretion and trigger apoptosis in activated CD8(+) Fas (CD95)(+) T lymphocytes. , 2000, International immunology.
[80] A Steinle,et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. , 1999, Science.
[81] G. Ghali,et al. Soluble HLA in human body fluids. , 1999, Human immunology.
[82] F. Otto,et al. Soluble HLA class I antigens in plasma of patients with malignant melanoma. , 1998, Anticancer research.
[83] J. Bell,et al. Structure and function of the human MHC class Ib molecules HLA‐E, HLA‐F and HLA‐G , 1998, Immunological reviews.
[84] S. Bauer,et al. Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. , 1998, Science.
[85] S. Ferrone,et al. Soluble HLA antigens: new roles and uses. , 1997, Immunology today.
[86] M. Krönke,et al. Soluble HLA class I molecules induce apoptosis in alloreactive cytotoxic T lymphocytes , 1996, Nature Medicine.
[87] J. Karbach,et al. Generation of cytotoxic T‐cell responses with synthetic melanoma‐associated peptides in vivo: Implications for tumor vaccines with melanoma‐associated antigens , 1996, International journal of cancer.
[88] N. Cascinelli,et al. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGES‐3 , 1995, International journal of cancer.
[89] G. Trinchieri,et al. Regulation of NK cell functions by TGF-beta 1. , 1995, Journal of immunology.
[90] S. Ferrone,et al. Serum HLA class I antigens: markers and modulators of an immune response? , 1995, Immunology today.
[91] Y. Nagamachi,et al. Quantification of serum-soluble HLA class I antigens in patients with gastric cancer. , 1994, Human immunology.
[92] S. Demaria,et al. Soluble beta 2-microglobulin-free class I heavy chains are released from the surface of activated and leukemia cells by a metalloprotease. , 1994, The Journal of biological chemistry.
[93] D. Tuveson,et al. A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[94] H. Tilg,et al. Enhanced serum levels of soluble HLA class I molecules are induced by treatment with recombinant interferon‐gamma (IFN‐γ) , 1991, Clinical and experimental immunology.
[95] P. Natali,et al. Class I major histocompatibility complex enhancement by recombinant leukocyte interferon in the peripheral blood mononuclear cells and plasma of melanoma patients. , 1991, Cancer research.
[96] D. Ruiter,et al. Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. , 1988, Cancer research.
[97] M. Krangel. Secretion of HLA-A and -B antigens via an alternative RNA splicing pathway , 1986, The Journal of experimental medicine.
[98] S. Pestka,et al. Modulation by recombinant DNA leukocyte (alpha) and fibroblast (beta) interferons of the expression and shedding of HLA- and tumor-associated antigens by human melanoma cells. , 1984, Journal of immunology.
[99] J. Coligan,et al. The NKG2D receptor: immunobiology and clinical implications , 2008, Immunologic research.
[100] M. Büchler,et al. Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing gammadelta T cell cytotoxicity. , 2006, International journal of cancer.
[101] F. Hodi,et al. Combinatorial cancer immunotherapy. , 2006, Advances in immunology.
[102] Hyunkeun Song,et al. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression. , 2006, Cellular immunology.
[103] T. Whiteside,et al. Immune Escape: Tumor induced immune suppression and immune escape: Mechanisms and Possible Solutions , 2005 .
[104] P. Tassone,et al. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. , 2005, Blood.
[105] S. Ferrone,et al. Classical and nonclassical HLA class I antigen and NK Cell-activating ligand changes in malignant cells: current challenges and future directions. , 2005, Advances in cancer research.
[106] I. Jordens,et al. Chaperoning antigen presentation by MHC class II molecules and their role in oncogenesis. , 2005, Advances in cancer research.
[107] J. Letterio. TGF-beta signaling in T cells: roles in lymphoid and epithelial neoplasia. , 2005, Oncogene.
[108] J. Neefjes,et al. Biochemical complexity of serum HLA class I molecules , 2004, Immunogenetics.
[109] S. Ferrone,et al. HLA antigen changes in malignant tumors of mammary epithelial origin: molecular mechanisms and clinical implications. , 2004, Breast disease.
[110] W. Cao,et al. UL16 binding proteins. , 2004, Immunobiology.
[111] J. Dausset,et al. HLA-G molecules: from maternal-fetal tolerance to tissue acceptance. , 2003, Advances in immunology.
[112] G. Bernardi,et al. Transendothelial migratory pathways of V delta 1+TCR gamma delta+ and V delta 2+TCR gamma delta+ T lymphocytes from healthy donors and multiple sclerosis patients: involvement of phosphatidylinositol 3 kinase and calcium calmodulin-dependent kinase II. , 2002, Journal of immunology.
[113] A. Balmain,et al. TGF-beta signaling in tumor suppression and cancer progression. , 2001, Nature genetics.
[114] S. Bahram,et al. MIC genes: from genetics to biology. , 2000, Advances in immunology.